Resources Repository
-
Lesson/ModuleWeb Portal, Teaching Resource 2016Placing a Bet: New Therapy for Parkinson's Disease
This module is intended for use by business school students. It examines the decision-making process …
This module is intended for use by business school students. It examines the decision-making process at a pharmaceutical company as its chief operating officer decides whether to invest in the development and licensing of a promising treatment for Parkinson’s disease. The module is structured around a drug development case that provides students with opportunities to: (1) analyze a rich and realistic description of the complex scientific and medical results associated with a promising therapeutic molecule…
Technology Assessment | Chronic Disease/Risk | Test Performance | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology | Global | North America | College | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
Lesson/ModuleWeb Portal, Teaching Resource 2016Educational Module: Drug-Induced Birth Defects
Using the currently topical issue of whether SSRI (Selective Serotonin Reuptake Inhibitor) anti-depressants cause birth …
Using the currently topical issue of whether SSRI (Selective Serotonin Reuptake Inhibitor) anti-depressants cause birth defects, the module aims to provide students with a general understanding of the following: (1) human risk factor causation as determined by epidemiologic methods; (2) the limits of non-human toxicological evidence to the assessment of causality in humans; (3) the importance of pharmacovigilance for all medications; (4) special difficulties in identifying causes of human birth defects; (5) the importance of…
Risk Analysis | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Child/Nutrition | Government/Law | Health/Medicine | Science/Technology | Global | North America | College | Graduate | Doctoral | Critical Thinking/Analysis | Quantitative Literacy -
ArticlePublication 2016Essential Package of Cancer Control: Costs, Affordability, and Feasibility of an Essential Package of Cancer Control Interventions in LMIC Countries
Investments in cancer control-prevention, detection, diagnosis, surgery, palliative care-are needed in low-income and particularly in …
Investments in cancer control-prevention, detection, diagnosis, surgery, palliative care-are needed in low-income and particularly in middle-income countries, where most of the world's cancer deaths occur without treatment or palliation. To help countries expand locally appropriate services, Disease Control Priorities, 3rd edition developed an essential package of potentially cost-effective measures for countries to consider and adapt. Interventions included in the package are: prevention of tobacco-related cancer and virus-related liver and cervical cancers; diagnosis and treatment of…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Costing Methods | Health Systems | Health/Medicine | Science/Technology | Global -
ArticlePublication 2016Estimating Benefits of Regulations Affecting Addictive Goods
The question of how to evaluate lost consumer surplus in benefit−cost analyses is controversial. There …
The question of how to evaluate lost consumer surplus in benefit−cost analyses is controversial. There are clear health benefits of regulations that curb consumption of goods with health risks, such as tobacco products and foods high in fats, calories, sugar, and sodium. Yet, if regulations cause consumers to give up goods they like, the health benefits they experience may be offset by some utility loss, which benefit−cost analyses of regulations need to take into account.…
Benefit-Cost Analysis | Mental Health | Decision Theory | Preferences/Values | Health/Medicine -
ArticlePublication 2016Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and …
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and treatment in U.S. prisons on the broader HCV epidemic. Employing an agent-based microsimulation model of HCV transmission and disease progression, data from published literature inform the analysis. The target populations include individuals in U.S. prisons and the general community over a 30-year timeframe, adopting a societal perspective. Interventions encompass risk-based and universal opt-out HCV screening in prisons, followed by treatment…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Microsimulation | Infectious Diseases | Health/Medicine | North America -
ReportPublication 2016Cost-Effectiveness of Mental, Neurological, and Substance Use Disorders
This report chapter reviews the available cost-effectiveness evidence for the different levels and underpinning strategies of …
This report chapter reviews the available cost-effectiveness evidence for the different levels and underpinning strategies of the mental health care system, with a focus on information generated in or for lower and middle income countries. First, the chapter reviews the economic evidence for mental health prevention and protection at the population and community levels of the health and welfare system, including legislative, regulatory, and informational measures at the public policy level (population platform), as well as…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Evidence Synthesis | Health Systems | Health/Medicine | Global -
ArticlePublication 2016An Extended CEA of Schizophrenia Treatment in India under Universal Public Finance
This paper evaluates the potential health and financial risk protection effects of a policy of …
This paper evaluates the potential health and financial risk protection effects of a policy of universal public finance (UPF) to treating schizophrenia in India. The study uses the extended cost effectiveness analysis framework across income quintiles. The results show financial protection benefits concentrated in the richest income quintiles, while health gains were concentrated among the poorest. The value of insurance is highest for the poorest income and decreases as the household income increases. In settings…
Cost-Effectiveness Analysis | Mental Health | Priority Setting/Ethics | Costing Methods | Health Systems | Clinical Care | Culture/Society | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2016UHC for Mental, Neurological, and Substance Use Disorders: An Extended CEA
This study uses extended cost effectiveness analysis (ECEA) to analyze the impacts of universal public …
This study uses extended cost effectiveness analysis (ECEA) to analyze the impacts of universal public finance (UPF) on epilepsy, schizophrenia, and depression in India and Ethiopia. The Ethiopian government has launched a National Mental Health Strategy which explicitly recognizes the importance of an efficient, equitable scale-up of mental health care within a broader, ongoing effort to increase levels of health insurance in the general population. The analyses show that enhanced coverage of effective treatment leads…
Cost-Effectiveness Analysis | Mental Health | Priority Setting/Ethics | Social Determinants | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2016Accounting for Technical, Ethical, and Political Factors in Priority Setting
This article investigates two cases of priority setting to explore how, in addition to technical …
This article investigates two cases of priority setting to explore how, in addition to technical considerations, ethical and political factors shape the allocation of health resources. First, they discuss how Thai authorities adjudicated a coverage decision for HLA-B*1502 screening, which meets the national cost-effectiveness threshold for only some of the conditions it can detect. Second, they consider England’s Cancer Drugs Fund to investigate the interplay of technical decision making and political reality. The findings suggest four concluding…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Priority Setting/Ethics | Health Systems | Policy/Regulation | Climate/Environment | Government/Law | Health/Medicine | Science/Technology | Global | Europe